The association of tumor-infiltrating lymphocytes (TILs) with improved prognosis in invasive breast cancer, particularly HER2 and triple negative subtypes, led to an assumption that TILs assessment of H&E samples can provide a similar prognostic value in DCIS. The gene discussed is ERBB2; the disease is invasive breast carcinoma.